Ependymoma Terminated Phase 2 Trials for Erlotinib (DB00530)

Also known as: Brain Ependymoma / Ependymoma of Brain / Ependymomas / Ependymoma (morphologic abnormality) / Ependymoma (disorder) / Ependymoma of brain (disorder)

IndicationStatusPhase
DBCOND0017183 (Ependymoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01247922Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205Treatment